Industry Cites Lack of Guidance in Proposed Combo GMP Rule

Washington Drug Letter
Combination-product stakeholders suggest that the FDA’s proposed rule on good manufacturing practices (GMPs) for those products add postapproval change control guidance, simplify other requirements and extend the waiting period for the rule to take effect.

To View This Article:


Buy This Article Now

Add this article to your cart for $10.00